Literature DB >> 17507447

Cortical cholinergic denervation is associated with depressive symptoms in Parkinson's disease and parkinsonian dementia.

N I Bohnen1, D I Kaufer, R Hendrickson, G M Constantine, C A Mathis, R Y Moore.   

Abstract

AIM: To investigate the relationship between ratings of depressive symptoms and in vivo cortical acetylcholinesterase (AChE) activity in subjects with Parkinson's disease (PD) and parkinsonian dementia (PDem).
METHODS: Subjects (with PD, n = 18, including subjects with PDem, n = 6, and normal controls, n = 10) underwent [11C]methyl-4-piperidinyl propionate AChE positron emission tomography imaging and clinical assessment including the Cornell Scale for Depression in Dementia (CSDD).
RESULTS: Subjects with PD and PDem had higher scores on the CSDD compared with normal controls: 7.3 (5.4) and 2.8 (2.6), respectively (F = 6.9, p = 0.01). Pooled analysis demonstrated a significant inverse correlation between cortical AChE activity and CSDD scores: R = -0.5, p = 0.007. This correlation remained significant after controlling for Mini-Mental State Examination scores.
CONCLUSION: Depressive symptomatology is associated with cortical cholinergic denervation in PD that tends to be more prominent when dementia is present.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17507447      PMCID: PMC2077949          DOI: 10.1136/jnnp.2006.100073

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  16 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  The serotonergic hypothesis for depression in Parkinson's disease: an experimental approach.

Authors:  Albert F G Leentjens; Bart Scholtissen; Fred W Vreeling; Frans R J Verhey
Journal:  Neuropsychopharmacology       Date:  2006-05       Impact factor: 7.853

3.  Synthesis of 1-[11C]methylpiperidin-4-yl propionate ([11C]PMP) for in vivo measurements of acetylcholinesterase activity.

Authors:  S E Snyder; L Tluczek; D M Jewett; T B Nguyen; D E Kuhl; M R Kilbourn
Journal:  Nucl Med Biol       Date:  1998-11       Impact factor: 2.408

4.  Cornell Scale for Depression in Dementia.

Authors:  G S Alexopoulos; R C Abrams; R C Young; C A Shamoian
Journal:  Biol Psychiatry       Date:  1988-02-01       Impact factor: 13.382

5.  Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Parkinson Study Group.

Authors:  J H Growdon; K Kieburtz; M P McDermott; M Panisset; J H Friedman
Journal:  Neurology       Date:  1998-05       Impact factor: 9.910

6.  Executive dysfunction and the course of geriatric depression.

Authors:  George S Alexopoulos; Dimitris N Kiosses; Moonseong Heo; Christopher F Murphy; Bindu Shanmugham; Faith Gunning-Dixon
Journal:  Biol Psychiatry       Date:  2005-08-01       Impact factor: 13.382

Review 7.  Antidepressant studies in Parkinson's disease: a review and meta-analysis.

Authors:  Daniel Weintraub; Knashawn H Morales; Paul J Moberg; Warren B Bilker; Catherine Balderston; John E Duda; Ira R Katz; Matthew B Stern
Journal:  Mov Disord       Date:  2005-09       Impact factor: 10.338

8.  Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease.

Authors:  Daniel Weintraub; Paul J Moberg; John E Duda; Ira R Katz; Matthew B Stern
Journal:  J Am Geriatr Soc       Date:  2004-05       Impact factor: 5.562

9.  The frequency and associated risk factors for dementia in patients with Parkinson's disease.

Authors:  K Marder; M X Tang; L Cote; Y Stern; R Mayeux
Journal:  Arch Neurol       Date:  1995-07

10.  Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system.

Authors:  Philippe Remy; Miroslava Doder; Andrew Lees; Nora Turjanski; David Brooks
Journal:  Brain       Date:  2005-02-16       Impact factor: 13.501

View more
  22 in total

Review 1.  Stress, depression and Parkinson's disease.

Authors:  Ann M Hemmerle; James P Herman; Kim B Seroogy
Journal:  Exp Neurol       Date:  2011-10-06       Impact factor: 5.330

2.  Correlation among olfactory function, motors' symptoms, cognitive impairment, apathy, and fatigue in patients with Parkinson's disease.

Authors:  Carla Masala; Paolo Solla; A Liscia; G Defazio; L Saba; A Cannas; A Cavazzana; T Hummel; A Haehner
Journal:  J Neurol       Date:  2018-05-26       Impact factor: 4.849

3.  Chronic escitalopram treatment restores spatial learning, monoamine levels, and hippocampal long-term potentiation in an animal model of depression.

Authors:  V Bhagya; B N Srikumar; T R Raju; B S Shankaranarayana Rao
Journal:  Psychopharmacology (Berl)       Date:  2010-11-04       Impact factor: 4.530

4.  Basal and Evoked Neurotransmitter Levels in Parkin, DJ-1, PINK1 and LRRK2 Knockout Rat Striatum.

Authors:  Rose B Creed; Liliana Menalled; Bradford Casey; Kuldip D Dave; Holden B Janssens; Isaac Veinbergs; Marieke van der Hart; Arash Rassoulpour; Matthew S Goldberg
Journal:  Neuroscience       Date:  2019-04-25       Impact factor: 3.590

Review 5.  Imaging the Etiology of Apathy, Anxiety, and Depression in Parkinson's Disease: Implication for Treatment.

Authors:  Stephane Thobois; Stephane Prange; Véronique Sgambato-Faure; Léon Tremblay; Emmanuel Broussolle
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08-18       Impact factor: 5.081

Review 6.  Nonmotor fluctuations: phenotypes, pathophysiology, management, and open issues.

Authors:  Joseph Classen; Jiri Koschel; Christian Oehlwein; Klaus Seppi; Peter Urban; Christian Winkler; Ullrich Wüllner; Alexander Storch
Journal:  J Neural Transm (Vienna)       Date:  2017-07-12       Impact factor: 3.575

Review 7.  Molecular Imaging of the Cholinergic System in Parkinson's Disease.

Authors:  Nicolaas I Bohnen; Prabesh Kanel; Martijn L T M Müller
Journal:  Int Rev Neurobiol       Date:  2018-09-20       Impact factor: 3.230

Review 8.  Depression in Parkinson disease--epidemiology, mechanisms and management.

Authors:  Dag Aarsland; Sven Påhlhagen; Clive G Ballard; Uwe Ehrt; Per Svenningsson
Journal:  Nat Rev Neurol       Date:  2011-12-26       Impact factor: 42.937

Review 9.  Depression and Parkinson's disease: current knowledge.

Authors:  Laura Marsh
Journal:  Curr Neurol Neurosci Rep       Date:  2013-12       Impact factor: 5.081

10.  Abnormal short latency afferent inhibition in early Alzheimer's disease: a transcranial magnetic demonstration.

Authors:  Raffaele Nardone; Jürgen Bergmann; Martin Kronbichler; Alexander Kunz; Stefanie Klein; Francesca Caleri; Frediano Tezzon; Gunther Ladurner; Stefan Golaszewski
Journal:  J Neural Transm (Vienna)       Date:  2008-10-08       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.